July 28, 2003Journal of VirologyOpen Access

Replication-Competent Bacterial Artificial Chromosomes of Marek's Disease Virus: Novel Tools for Generation of Molecularly Defined Herpesvirus Vaccines

Q: What is the clinical evidence from this study?

Population: Marek's disease (n=99). Intervention: pCVI988 clone 10 (BAC-derived virus or BAC DNA) vs. Uninfected CEF, tissue culture medium, or transfer vector pDS-pHA1. Primary outcome: Protection against virulent RB1B strain challenge (absence of Marek's disease).

View Full Paper

Ask AI

Bookmark

Key result

Vaccination with BAC-derived CVI988 virus induced 100% protection against virulent Marek's disease virus challenge in chicks, while the BAC DNA vaccine induced protection in 33.3% of birds.

Population

1-day-old specific-pathogen-free HPRS Rhode Island Red chicks

Comparison

pCVI988 clone 10-derived virus or naked DNA of… vs Uninfected chicken embryo fibroblasts, tissue…

Design

Preclinical

Follow-up

8 weeks

Authors

KHK. HowesThe Pirbright Institute SBSusan J. BaigentThe Pirbright Institute MSMelanie A. SaccoMagna Graecia University

Discussion

Member takes

Implication

BAC-derived CVI988 confers full protection in this chick model; leaves open whether BAC technology yields effective DNA vaccines for herpesviruses.

Structured PICO

Population

99 1-day-old specific-pathogen-free chicks were used to evaluate the protective efficacy of BAC-derived CVI988 virus and DNA vaccines against virulent Marek's disease virus challenge over 8 weeks.

Intervention

pCVI988 clone 10-derived virus (1,000 PFU intra-abdominally) or naked DNA of pCVI988 clone 10 (5 µg or 10 µg intramuscularly)

Comparator

Uninfected chicken embryo fibroblasts (CEF), tissue culture medium, or transfer vector pDS-pHA1 (5 µg or 10 µg)

Outcome

Development of Marek's disease based on gross and histological lesions after challenge with virulent RB1B strainhard clinical

Main Result

Absolute Event Rate: 100% vs 0%

BAC-derived CVI988 virus provides 100% protection against virulent Marek's disease virus, demonstrating the potential of BAC technology for generating molecularly defined herpesvirus vaccines.

Limitations

Suboptimal method of DNA delivery may have resulted in the lower protection rate for the DNA vaccine.
Did not examine tissues of all DNA-vaccinated birds for evidence of virus replication to confirm the mechanism of protection.
suboptimal method of DNA delivery

Cite This Study

Howes et al. (2003) studied Marek's disease (n=99). pCVI988 clone 10 (BAC-derived virus or BAC DNA) vs. Uninfected CEF, tissue culture medium, or transfer vector pDS-pHA1 was evaluated on Protection against virulent RB1B strain challenge (absence of Marek's disease). Vaccination with BAC-derived CVI988 virus induced 100% protection against virulent Marek's disease virus challenge in chicks, while the BAC DNA vaccine induced protection in 33.3% of birds.

synapsesocial.com/papers/6a9d7e6ad8a02169be46e978 https://doi.org/10.1128/jvi.77.16.8712-8718.2003

View Full Paper

Ask AI

Bookmark

Implication

BAC-derived CVI988 confers full protection in this chick model; leaves open whether BAC technology yields effective DNA vaccines for herpesviruses.

Replication-Competent Bacterial Artificial Chromosomes of Marek's Disease Virus: Novel Tools for Generation of Molecularly Defined Herpesvirus Vaccines

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Replication-Competent Bacterial Artificial Chromosomes of Marek's Disease Virus: Novel Tools for Generation of Molecularly Defined Herpesvirus Vaccines

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider